Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding Equity

The The Equity of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Nov 8, 2026 is 3.80 B CNY. In the previous year, The Equity was 3.92 B CNY — a change of -3.05% (lower).

Equity

3.80 BCNY

YoY

-3.05%

Last updated:

In 2025, Tibet Rhodiola Pharmaceutical Holding's equity was 3.80 B CNY, a -3.05% increase from the 3.92 B CNY equity in the previous year.

The Tibet Rhodiola Pharmaceutical Holding Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
2.25 B CNY
Jan 1, 2019
2.44 B CNY
Jan 1, 2020
2.58 B CNY
Jan 1, 2021
2.63 B CNY
Jan 1, 2022
3.01 B CNY
Jan 1, 2023
3.34 B CNY
Jan 1, 2024
3.92 B CNY
Jan 1, 2025
3.80 B CNY
The Tibet Rhodiola Pharmaceutical Holding Equity history
YEAREquityYoY
3.80 BCNY-3.05%
3.92 BCNY+17.14%
3.34 BCNY+11.05%
3.01 BCNY+14.50%
2.63 BCNY+2.11%
2.58 BCNY+5.70%
2.44 BCNY+8.19%
2.25 BCNY+10.24%
2.04 BCNY+209.28%
660.64 MCNY+34.97%
489.45 MCNY+21.05%
404.35 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Tibet Rhodiola Pharmaceutical Holding's Equity

Tibet Rhodiola Pharmaceutical Holding's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Tibet Rhodiola Pharmaceutical Holding's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Tibet Rhodiola Pharmaceutical Holding's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Tibet Rhodiola Pharmaceutical Holding's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Tibet Rhodiola Pharmaceutical Holding’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

The Equity of Tibet Rhodiola Pharmaceutical Holding is 3.80 B CNY in 2025.

The Equity of Tibet Rhodiola Pharmaceutical Holding changed from 3.92 B CNY to 3.80 B CNY, representing a -3.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Tibet Rhodiola Pharmaceutical Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tibet Rhodiola Pharmaceutical Holding

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding